Osthol attenuates hepatic steatosis via decreased triglyceride synthesis not by insulin resistance

World Journal of Gastroenterology

Volumn 20, Issue 33, 2014, Pages 11753-11761

  Nam, Ho Hyun ^a   Jun, Dae Won ^a   Jeon, Hye Joon ^a   Lee, Jai Sun ^a   Saeed, Waqar Khalid ^a   Kim, Eun Kyung ^b  

^a Hanyang University   (South Korea)

^b Eulji University   (South Korea)

Author keywords

Non alcoholic fatty liver disease; Osthol; Sterol regulatory element binding protein

Indexed keywords

ACYL COENZYME A DESATURASE 1; CARNITINE OCTANOYLTRANSFERASE; FATTY ACID SYNTHASE; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTHOLE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRANSFERASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; COUMARIN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FAT CONTENT; FATTY ACID OXIDATION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INSULIN RESISTANCE; LIPOGENESIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; ANIMAL; BIOSYNTHESIS; DISEASE MODEL; DRUG EFFECTS; LIPID DIET; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; TIME;

ANIMALS; BIOLOGICAL MARKERS; COUMARINS; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; INSULIN RESISTANCE; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; RATS, SPRAGUE-DAWLEY; TIME FACTORS; TRIGLYCERIDES;

EID: 84909608173     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i33.11753     Document Type: Article

References (28)

1. Lazo M, Hernaez R, Bonekamp S, Kamel IR, Brancati FL, Guallar E, Clark JM. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ 2011; 343: d6891 [PMID: 22102439]
2. Wong VW, Chu WC, Wong GL, Chan RS, Chim AM, Ong A, Yeung DK, Yiu KK, Chu SH, Woo J, Chan FK, Chan HL. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012; 61: 409-415 [PMID: 21846782]
3. Targher G, Byrne CD. Clinical Review: Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab 2013; 98: 483-495 [PMID: 23293330]
4. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010; 52: 1836-1846 [PMID: 21038418 DOI: 10.1002/hep.24001]
5. Koteish A, Mae Diehl A. Animal models of steatohepatitis. Best Pract Res Clin Gastroenterol 2002; 16: 679-690 [PMID: 12406439]
6. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-1685 [PMID: 20427778]
7. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231 [PMID: 11961152]
8. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005; 42: 987-1000 [PMID: 16250043]
9. Ratziu V, Charlotte F, Bernhardt C, Giral P, Halbron M, Lenaour G, Hartmann-Heurtier A, Bruckert E, Poynard T. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 2010; 51: 445-453 [PMID: 19877169 DOI: 10.1002/hep.23270]
10. Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, Podevin P, Lacorte JM, Bernhardt C, Bruckert E, Grimaldi A, Poynard T. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008; 135: 100-110 [PMID: 18503774]
11. Mehta K, Van Thiel DH, Shah N, Mobarhan S. Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants. Nutr Rev 2002; 60: 289-293 [PMID: 12296456]
12. Miller ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142: 37-46 [PMID: 15537682]
13. Qi Z, Xue J, Zhang Y, Wang H, Xie M. Osthole ameliorates insulin resistance by increment of adiponectin release in high-fat and high-sucrose-induced fatty liver rats. Planta Med 2011; 77: 231-235 [PMID: 20717873 DOI: 10.1055/s-0030-1250268]
14. Zhang Y, Xie ML, Xue J, Gu ZL. Osthole regulates enzyme protein expression of CYP7A1 and DGAT2 via activation of PPARalpha/gamma in fat milk-induced fatty liver rats. J Asian Nat Prod Res 2008; 10: 807-812 [PMID: 18696335 DOI: 10.1080/10286020802102303]
15. Zhang J, Xue J, Wang H, Zhang Y, Xie M. Osthole improves alcohol-induced fatty liver in mice by reduction of hepatic oxidative stress. Phytother Res 2011; 25: 638-643 [PMID: 20981870 DOI: 10.1002/ptr.3315]
16. Zhang Y, Xie ML, Zhu LJ, Gu ZL. Therapeutic effect of osthole on hyperlipidemic fatty liver in rats. Acta Pharmacol Sin 2007; 28: 398-403 [PMID: 17303003 DOI: 10.1111/j.1745-7254.2007.00533.x]
17. Zhang Y, Xie M, Xue J, Gu Z. Osthole improves fat milk-induced fatty liver in rats: modulation of hepatic PPARalpha/gamma-mediated lipogenic gene expression. Planta Med 2007; 73: 718-724 [PMID: 17611927 DOI: 10.1055/s-2007-981552]
18. Ota T, Takamura T, Kurita S, Matsuzawa N, Kita Y, Uno M, Akahori H, Misu H, Sakurai M, Zen Y, Nakanuma Y, Kaneko S. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology 2007; 132: 282-293 [PMID: 17241878 DOI: 10.1053/j.gastro.2006.10.014]
19. Tessari P, Coracina A, Cosma A, Tiengo A. Hepatic lipid metabolism and non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2009; 19: 291-302 [PMID: 19359149]
20. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997; 89: 331-340 [PMID: 9150132]
21. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004; 114: 147-152 [PMID: 15254578]
22. Shimomura I, Shimano H, Horton JD, Goldstein JL, Brown MS. Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells. J Clin Invest 1997; 99: 838
23. Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ 2005; 172: 899-905 [PMID: 15795412]
24. Shimomura I, Bashmakov Y, Horton JD. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem 1999; 274: 30028-30032 [PMID: 10514488]
25. Kohjima M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, Fujino T, Yada M, Yada R, Harada N, Enjoji M, Takayanagi R, Nakamuta M. SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease. Int J Mol Med 2008; 21: 507-511 [PMID: 18360697]
26. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995; 22: 1714-1719 [PMID: 7489979]
27. Sun F, Xie ML, Xue J, Wang HB. Osthol regulates hepatic PPAR alpha-mediated lipogenic gene expression in alcoholic fatty liver murine. Phytomedicine 2010; 17: 669-673 [PMID: 20042322]
28. Skrha J, Haas T, Sindelka G, Prázný M, Widimský J, Cibula D, Svacina S. Comparison of the insulin action parameters from hyperinsulinemic clamps with homeostasis model assessment and QUICKI indexes in subjects with different endocrine disorders. J Clin Endocrinol Metab 2004; 89: 135-141 [PMID: 14715840]